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Although initially described as the end state of cells after extended rounds of division in culture, it 
is now clear that cellular senescence induced by different stimuli plays an important role in tumor 
suppression in vivo. Three recent studies in Cell report that secreted proteins play an important role 
in enforcing the senescence response (Acosta et al., 2008; Kuilman et al., 2008; Wajapeyee et al., 
2008). These new studies identify unanticipated contributors to this tumor-suppressing cell state.Cellular senescence is characterized by irreversible proliferative 
arrest and distinctive morphological alterations. Although origi-
nally described in human fibroblasts at the end of their replicative 
life span, it is now clear that senescence can be induced both 
in vitro and in vivo by a pleiotropic group of stimuli that include 
oncogene activation, telomere dysfunction, and agents that dam-
age DNA or alter chromatin structure (Campisi and d’Adda di 
Fagagna, 2007). These observations support the view that similar 
to apoptosis, senescence is a programmed cellular response that 
can be triggered by a variety of stresses. Abundant recent work 
indicates that senescence serves as an important mechanism of 
tumor suppression that is activated in benign lesions (Braig et al., 
2005; Chen et al., 2005; Collado et al., 2005; Courtois-Cox et al., 
2006; Michaloglou et al., 2005). Senescence is also implicated in 
the loss of regenerative potential in aging tissues. The loss of pro-
liferative potential in senescent cells contributes to diminished tis-
sue function (reviewed in Campisi and d’Adda di Fagagna, 2007). 
Moreover, because senescent cells remain metabolically active, it 
has been proposed that these cells may also play a role in tissue 
aging by either positively or negatively influencing the neighboring 
tissue microenvironment. Thus, senescence may serve as a key 
mechanistic link between aging and cancer.
At the molecular level, the p53 and retinoblastoma (RB) tumor 
suppressor pathways serve as critical cell-cycle checkpoints 
that mediate both replicative and oncogene-induced senes-
cence. Although recent work has begun to identify the molecules 
that enforce senescence in response to different signals, we 
still have only a rudimentary understanding of the components 
that comprise and execute the senescence program. Indeed, 
no truly validated molecular markers exist to identify senescent 
cells. In this context, three groups (Acosta et al., 2008; Kuilman 
et al., 2008; Wajapeyee et al., 2008) used unbiased genomic 
approaches to identify specific secreted proteins that play an 
essential role in oncogene-induced senescence. These unex-
pected findings add another level of complexity to our under-
standing of senescence and its role in aging and cancer.958 Cell 133, June 13, 2008 ©2008 Elsevier Inc.Both Wajapeyee et al. (2008) and Acosta et al. (2008) used 
loss-of-function screens in cultured diploid human fibroblasts 
to identify genes required to induce senescence. Wajapeyee 
et al. made use of an oncogenic allele of the serine/threonine 
kinase BRAF (BRAFV600E) that contains a mutation known to 
occur with high frequency in malignant melanomas. After con-
firming that the expression of BRAFV600E in the fibroblasts was 
sufficient to induce senescence and apoptosis, the authors 
introduced into the BRAFV600E-expressing cells a short hair-
pin RNA (shRNA) library targeting human genes. Using this 
approach, they identified 17 genes whose suppression per-
mitted the cells to proliferate in the presence of BRAFV600E. Of 
these genes, one encoded the insulin-like growth factor binding 
protein 7 (IGFBP7), a secreted protein previously implicated in 
senescence in breast cancer cells (Wilson et al., 2002). IGFBP7 
is a low-affinity insulin-like growth factor (IGF) binding protein 
(Burger et al., 2005). Although it is not known whether IGFBP7 
mediates its effects by binding and suppressing IGF proteins, it 
is notable that IGFs have long been suspected to promote tum-
origenesis. Indeed, therapeutic strategies focused on inhibiting 
the IGF signaling pathway are currently under development.
Wajapeyee and colleagues showed that BRAFV600E upreg-
ulated IGFBP7 expression at least in part through stimulat-
ing the binding of the transcription factor activator protein 1 
(AP-1) to the IGFBP7 promoter. Consistent with the hypoth-
esis that IGFBP7 suppresses BRAF-driven tumor develop-
ment in vivo, melanomas that harbored BRAFV600E mutations 
exhibited hypermethylation of a CpG island in the IGFBP7 
promoter relative to either benign lesions (nevi) that har-
bored BRAFV600E or melanomas that lacked the BRAFV600E 
oncogene. Interestingly, cultured melanocytes expressing 
BRAFV600E were sensitive to IGFBP7 in the culture media, 
which was sufficient to induce apoptosis. Taken together, 
these observations implicate IGFBP7 as an essential com-
ponent of an autocrine/paracrine feedback loop that con-
strains BRAFV600E-stimulated cell proliferation.
Acosta et al. (2008) used a similar approach to search for 
genes that extended the life span of IMR-90 cultured human 
fibroblasts and found that the chemokine receptor CXCR2 was 
required for replicative senescence and oncogene-induced 
senescence. Furthermore, overexpression of CXCR2 or the 
CXCR2 ligands interleukin-8 (IL-8) and GROα/Gro-1 led to a 
proliferative arrest that was dependent upon the expression 
of p53. Notably, expression of oncogenic RAS was previously 
shown to enhance Gro-1 expression and to induce senescence 
of murine stromal fibroblasts, underscoring the importance of 
this chemokine secretory response in senescence (Yang et 
al., 2006). Indeed, these CXCR2 ligands were also found to be 
upregulated in cells rendered senescent by mitogen-activated 
kinase kinase (MEK) activation. Using small-molecule inhibi-
tors, Acosta et al. further demonstrated that blocking the p38 
and NF-κB pathways suppressed the observed induction of 
IL-8 expression by MEK. Finally, they showed that CXCR2 is 
upregulated in benign lesions such as chemically induced 
papillomas and prostate intraepithelial neoplastic lesions, sug-
gesting that this pathway is upregulated in spontaneously aris-
ing premalignant lesions.
In their new work, Kuilman et al. (2008) used whole-genome 
transcriptional analyses of cell lines expressing BRAFV600E in 
their search for senescence factors. Similar to what has been 
previously reported for replicative senescence (reviewed in 
Campisi and d’Adda di Fagagna, 2007), they found that of the 
many transcriptional changes observed in senescent cells, a 
significant number of the upregulated genes were involved in 
chemokine and cytokine signaling. In particular, Kuilman et al. 
found that IL-6 was reproducibly upregulated in BRAFV600E-
expressing cells, and they verified that suppression of IL-6 or 
its cognate receptor IL-6R was sufficient to allow these cells 
to re-enter the cell cycle and to proliferate, thereby bypass-
ing oncogene-induced senescence. However, overexpression 
of IL-6 alone was not sufficient to induce senescence, sug-
gesting that IL-6 acts in concert with other factors to initiate 
senescence. Indeed, the suppression of IL-8 resulted in similar 
biological effects as the suppression of IL-6. Kuilman et al. fur-
ther showed that the levels of the transcription factors C/EBP 
(CCAAT-enhancer-binding proteins) increased in oncogene-
induced senescence. They determined by chromatin immuno-
precipitation that C/EBP was present at both the IL-6 and IL-8 
promoters, suggesting a likely mechanism for the upregulation 
of these cytokines in senescence. Moreover, they found that 
IL-6 and C/EBP function in a positive feedback loop; both are 
required to amplify and sustain the inflammatory network and 
senescence. Importantly, similar to the findings of Acosta et 
al. (2008), Kuilman and colleagues showed that the expression 
of IL-8 correlated with a nonproliferative phenotype in colonic 
adenomas, supporting the possibility that these cytokines 
function in vivo to promote cell senescence in benign human 
tumors.
Although each of these three studies identified different 
genes involved in the senescence response, the common 
theme that emerges is that secreted proteins play a critical role 
in the induction and maintenance of some forms of oncogene-
induced senescence. Although surprising, these observations 
provide new insights into our understanding of oncogene-in-duced senescence. So, how do these findings interface with 
our current mechanistic understanding of oncogene-induced 
senescence and human tumor development?
Connections with Known Mediators of Senescence
At least three cellular responses to oncogenic stress have been 
proposed to mediate oncogene-induced senescence: hetero-
chromatin formation, activation of the DNA-damage response, 
and negative feedback suppression of oncogenic signaling 
pathways (reviewed in Campisi and d’Adda di Fagagna, 2007; 
Courtois-Cox et al., 2006). Importantly, these mechanisms of 
oncogene-induced senescence are not mutually exclusive and all 
of these processes are intimately connected to the activity of the 
RB and p53 pathways. The derepression of the INK4/ARF locus 
is one mechanism known to contribute to the activation of RB 
and p53 and to play a critical role in initiating and maintaining the 
senescence response. However, several lines of evidence sug-
gest that additional cooperative signals may exist. Although the 
details differ among these studies, the secreted proteins featured 
herein appear to provide such cooperative signals and to con-
verge with each of the existing senescence models (Figure 1).
Heterochromatin Formation
Although no universal marker of senescence has been 
described, many senescent cells undergo dramatic changes 
in chromatin structure and form easily visualized senescence-
associated heterochromatic foci (Narita et al., 2003). The for-
Figure 1. Secreted Proteins and Oncogene-Induced Senescence
Expression of an oncogenic allele of BRAF (BRAFV600E) in human cells induces 
senescence. Three recent genetic screens using cells expressing BRAFV600E 
identified the secreted proteins (green) insulin-like growth factor binding pro-
tein 7 (IGFBP7), interleukin 8 (IL-8), and interleukin 6 (IL-6) or their receptors as 
essential mediators of BRAFV600E-dependent senescence. These unexpected 
observations provide new insights into the overlapping yet distinct mecha-
nisms of activation of the p53 and RB tumor suppressor pathways that induce 
the senescence response. IGFBP7 expression is mediated by the transcrip-
tion factor activator protein 1 (AP-1; blue). IGFBP7 inhibits the MEK mitogen-
activated protein kinase pathway via the upregulation of the Raf inhibitory 
protein (RKIP) but in contrast promotes expression of p16. The transcription 
factor C/EBP (CCAAT-enhancer-binding protein; blue) promotes expression 
of IL-6. The activity of the cytokine is mediated by its receptor IL-6R. The 
chemokine receptor CXCR or its ligands IL-8 and GRO-α promote p53-de-
pendent senescence. IL-8 upregulation is dependent upon the transcripton 
factors C/EBP and NF-κB.Cell 133, June 13, 2008 ©2008 Elsevier Inc. 959
mation of these foci requires the recruitment of RB and het-
erochromatin proteins (Adams, 2007; Narita et al., 2003). This 
provides a plausible mechanism for the stable suppression 
of E2F target genes and other genes necessary to enforce 
an irreversible senescent state. One RB pathway regulator, 
p16INK4a, has been shown to be essential for oncogene-induced 
senescence in vivo and in vitro. However, others have noted 
that p16INK4a is not expressed in every senescent cell within 
BRAFV600E-expressing melanocytic nevi, supporting the notion 
that other signals contribute to the activation of RB in some 
settings (Michaloglou et al., 2005). One such signal may be the 
cyclin kinase inhibitor p15INK4b, which was identified as a marker 
of Ras-induced senescence (Collado et al., 2005). The work 
of Kuilman et al. (2008) provides an interesting link between 
p15INK4b, heterochromatin, and the IL-6/C/EBP pathway. Spe-
cifically, inactivation of IL-6 or C/EBP not only prevented the 
proliferative arrest triggered by oncogenic BRAFV600E but also 
inhibited p15INK4b expression and senescence-associated het-
erochromatic foci formation. Notably, C/EBP has previously 
been shown to bind and activate the p15INK4b promoter (Gomis 
et al., 2006), providing a mechanistic explanation for these find-
ings. Taken together, these observations suggest that IL-6 and 
C/EBP coordinately function to upregulate p15INK4b expression, 
which in turn contributes toward RB activation, senescence-
associated heterochromatic foci formation, and oncogene-
induced senescence.
DNA Damage
Oncogene-induced senescence can be mediated by DNA 
damage associated with replicative stress or the accumula-
tion of reactive oxygen species (ROS) (Bartkova et al., 2006; 
Di Micco et al., 2006; Mallette et al., 2007). Following the iden-
tification of CXCR as a factor involved in senescence, Acosta 
and coworkers directly explored a role for chemokine signaling 
in the DNA-damage response. Specifically, they showed that 
inactivation of CXCR2 inhibited the DNA-damage response 
and abrogated the proliferative arrest of irradiated fibroblasts. 
In addition, CXCR2-induced senescence and senescence-
associated heterochromatic foci formation depended on func-
tional p53 (in murine cells) or p53 and RB (in human cells). 
Further work is necessary to decipher the effects of CXCR2 
ablation on the DNA-damage response and on p53 expression 
in response to oncogenic stress. However, these observations 
do suggest that excessive CXCR signaling during oncogene-
induced senescence may allow for increased ROS accumula-
tion, thus promoting the DNA-damage response and sustained 
activation of p53.
Negative Feedback Signaling
Wajapeyee et al. suggest that IGFBP7 mediates its antipro-
liferative effects via the induction of a negative feedback sig-
naling response. Specifically, they showed that conditioned 
media from IGFBP7-expressing cells or recombinant IGFBP7 
purified from baculovirus-infected insect cells potently sup-
pressed the activation of the mitogen-activated protein 
kinase (MAPK) ERK. Moreover, they demonstrated that this 
suppressive effect in melanoma cells was largely mediated 
by the upregulation of Raf inhibitory protein (RKIP), a protein 
that disrupts the interaction between upstream activators of 
ERK, Raf, and MEK. Importantly, the antiproliferative effects 960 Cell 133, June 13, 2008 ©2008 Elsevier Inc.of IGFBP7 in melanoma cells were suppressed by the ectopic 
expression of an activated ERK2 or MEK allele. Thus, Wajap-
eyee et al. concluded that the suppression of cell proliferation 
conferred by IGFBP7 is mediated, in part, by a negative feed-
back signal that emanates from the initial oncogenic insult. 
These findings are conceptually similar to another report 
demonstrating that a negative feedback signaling network 
involving multiple negative regulatory genes is activated by 
an oncogenic allele of RAF during oncogene-induced senes-
cence (Courtois-Cox et al., 2006). Given that other studies 
have demonstrated that perturbation of components of the 
Ras/phosphatidylinositol 3-kinase (PI3K) signaling pathways 
also contributes to oncogene-induced senescence (Chen et 
al., 2005; Courtois-Cox et al., 2006), perhaps negative feed-
back suppression of both the MEK/ERK and PI3K pathways 
cooperate to mediate senescence and tumor suppression. 
This model is supported by the observation that both the 
ERK and PI3K pathways are inactive in some benign human 
tumors (Courtois-Cox et al., 2006).
Mediating Senescence by A Threshold Response
The process of oncogene-induced senescence appears to be 
dependent on a rapidly growing list of genes. How then is it 
possible that the inactivation of any one gene can block senes-
cence? There are two nonmutually exclusive possibilities. First, 
although it is clear that p53- and RB-regulated senescence 
can be induced by many stimuli, the activation of the p53 or 
RB cell-cycle checkpoint under normal cellular contexts fails 
to induce a senescence response. Therefore, it is likely that an 
enhancement of the amplitude and/or duration of the Rb/p53 
signal, above a certain threshold, is necessary to trigger an 
irreversible proliferative arrest. For example, although p16INK4a 
is certainly an important regulator of oncogene-induced senes-
cence, it is possible that other cyclin kinase inhibitors such as 
p15INK4b reinforce and amplify this signal. Similarly, the DNA-
damage response pathway serine/threonine kinase ATM and 
the p53 regulator ARF may collaborate in response to certain 
oncogenic insults to potentiate p53 activation (Bartkova et al., 
2006; Di Micco et al., 2006; Mallette et al., 2007).
A second possibility is that the activation of pathways 
linked to senescence triggers a positive feedback loop nec-
essary to enforce the senescence response. Indeed, Kuil-
man and colleagues demonstrated that the cytokine IL-6 
and C/EBP form this type of feedback loop and observed 
that in the absence of either of these two proteins, the entire 
network of signaling pathways that regulate the inflamma-
tory response is disrupted.
Although such thresholds and feedback loops in this system 
are as yet incompletely defined, these models could explain 
how multiple different signals may cooperate to induce the 
senescence response in different contexts. If the threshold 
response model is correct, the level and strength of oncogenic 
signals should be carefully considered when interpreting stud-
ies of oncogene-induced senescence. In addition, whereas 
the term oncogene-induced senescence is generally used to 
describe senescence triggered by any oncogenic insult, it is 
likely that specific oncogenes may be attenuated by different 
inhibitory signals. Consistent with this notion, Wajapeyee et al. 
showed that melanomas expressing a mutant RAS allele were 
much less sensitive to the inhibitory effects of IGFBP7 relative 
to melanomas harboring the BRAFV600E allele.
Regardless of the details of how senescence may be initi-
ated, these new findings have important implications for our 
understanding of tumor progression. Inactivation of any one of 
the proteins identified in the three screens in a specific setting 
may allow premalignant cells to bypass oncogene-induced 
senescence and thereby contribute toward the development of 
a malignant lesion. Thus, identification of signals that promote 
senescence in a given tumor type may provide new therapeu-
tic targets for cancer. The observation that mice harboring 
human tumor xenografts treated with recombinant IGFBP7 
show tumor growth suppression lends support to this possibil-
ity (Wajapeyee et al., 2008).
The genes identified in these studies clearly act to promote 
senescence in an autocrine manner because the gene prod-
ucts are secreted factors. However, it is also necessary to con-
sider the consequences of upregulating these genes in situ. In 
particular, it has been reported that senescent cells can induce 
their own clearance (Xue et al., 2007). Alternatively, senescent 
cells have also been observed to elicit effects on the tumor 
stroma that serve to enhance tumor growth (Krtolica et al., 
2001). Thus, depending on the context, these secreted pro-
teins may also serve to inhibit or to enhance cancer initiation 
and progression in addition to enforcing oncogene-induced 
senescence in a cell-autonomous manner. Despite the recent 
rapid progress in deciphering the molecular regulators and 
components of senescence, it is clear that we have only begun 
to unravel the complex regulation of cell senescence and its 
role in tumor suppression.
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